Grand Challenges in Diabetes by Vinik, Aaron
The magnitude of the diabetes epidemic – 
from its macrovascular (including heart 
attacks, strokes, and peripheral vascular 
disease) and the microvascular complica-
tions of diabetes (including retinopathy, 
nephropathy, neuropathy, and disorders 
of the integument and bone) – cannot be 
underestimated. In the US alone, an esti-
mated 25.8 million people have diabetes, 
primarily Type 2. In 2010, 1.9 million new 
cases were diagnosed in people age 20 or 
older, amounting to more than 3500 each 
day. One in three children born today will 
become diabetic, and there are 79 mil-
lion people in the US alone who are pre-
diabetic. Complications of diabetes are a 
major cause of mortality and morbidity. 
Each year, diabetes contributes to 224,000 
deaths, 96,000 amputations, or 1 amputa-
tion every 10 min in the US; 44,000 begin 
treatment for kidney failure; 12,000–24,000 
become blind; and the cost is becoming 
overwhelming. In 2007, the cost was $178 
billion, of which medical expenditures was 
$116 billion, with the indirect costs from 
loss of productivity estimated at $58 billion. 
Globally in 2003, there were 194 million and 
this is expected to increase by 2025 to 333 
million – a 72% increase. The hardest hit is 
Asia with an expected increase of 106%. To 
what can we attribute this explosion, clearly 
the diabetes explosion is following closely 
on the heels of the obesity pandemic. The 
LOOK AHEAD study has taught us that a 
healthy lifestyle can reduce the metabolic 
consequences of obesity (Wing et al., 2011), 
but it is naïve to think that this will deal 
with the global problem. What is needed 
are efforts to involve the legislators at city, 
state, nationally, and globally to find novel 
approaches to stemming this tide. In the 
meanwhile, a greater in-depth probing of 
the mechanisms of surgical approaches to 
reduction of calorie intake should surely 
lead to novel therapies for medically alter-
ing this landscape and for reducing the 
need for expensive and brutal surgery to 
counter a social disaster. The essential 
component of lifestyle management of 
obesity and diabetes is a change in physical 
activity, which unfortunately is an anath-
ema to most people and a leading cause of 
diabetes and obesity. We need innovative 
and creative, fun activities as surrogates to 
replace the traditional “exercise.” Physicians 
and health professionals should act as role 
models engaging in enjoyable physical 
activities with achievable goals and with 
social and physiological benefits. However, 
there clearly is a lesson to be learned from 
the fact that only about 30–40% of obese 
people develop type 2 diabetes although 
80–90% of type 2 diabetics are obese. 
What affords certain people this protection? 
Clinical and genetic risk factors identified 
in the Malmo study for this susceptibility 
include (HR): time period for either men or 
women (1.74), a first degree family history 
of diabetes (1.65), current smoking (1.39), 
increased body-mass index (per 1 SD, 1.49), 
increased fasting or 1 h postprandial plasma 
glucose (per 1 SD, 1.51), increased diastolic 
blood pressure (per 1 SD, 1.16), increased 
triglycerides (per 1SD, 1.28), increased 
y-glutamyltransferase (per 1 SD, 1.10), 
increased alanine aminotransferase (per 1 
SD, 1.37). So the question arises: “Are there 
no guaranteed risk predictors which need 
to be sought energetically, perhaps allowing 
an earlier window of opportunity in pre-
vention of progression?” Genetic studies of 
predisposition to T2D have now unearthed 
a combination of the risk alleles in 11 SNPs, 
and there are MODY genes which trans-
mit the condition as an autosomal domi-
nant – yet we can only account for <0.5% 
of the predisposition genetically. We need 
to do better and make a concerted effort, 
particularly now that we have the human 
genome in hand. An alternate to behavio-
ral and genetic approaches is to address the 
mechanistic aspects of the different forms 
of diabetes. In type 1 diabetes, we now have 
an understanding of the genetic predispo-
sition to autoimmune destruction of the 
pancreatic beta cells, the role of precipitat-
ing events, and how it ultimately devolves 
around a loss of beta cell mass and failure of 
islet regeneration by islet neogenesis or rep-
lication While there are agents that enhance 
neogenesis from proto-differentiated stem 
cells resident in the pancreas such as INGAP, 
the appropriate agents to curb the vicious 
inflammatory autoimmune attack have 
thus far escaped discovery. The gap between 
genomic stem cells, which, although prom-
ising, have yet to fulfill their promise, and 
alternative strategies using bone marrow 
or adipose tissue derived stem cells should 
receive greater attention as prospective 
therapies (Power and Rasko, 2011). There 
is a need to recapitulate fetal ontogeny, but 
there are elusive critical factors. However, 
the demonstration that adult stem cells can 
be reprogrammed ex vivo and tailored to 
generate the specific cells of interest is very 
encouraging. Our particular interest in this 
area has been using plasmids containing the 
genes of interest and injecting these into 
muscle or skin by electroporation, thereby 
creating a stable reproducing form of the 
gene of interest and its products. Similar 
approaches are likely to yield rewarding new 
therapeutic options. Furthering the under-
standing of the genetics and role of autoim-
mune mechanisms in type 1 diabetes and 
the genetics of type 2 diabetes are therefore 
topics of particular interest.
Inflammation is the buzz word of this 
decade. It seems that we can now attribute 
to inflammation a role in atheroma, beta 
cell destruction and even the microvascular 
complications of diabetes. What is not clear 
is whether this is a cause of the disorder, 
exerts a pathogenic role, or is simply an 
innocent bystander and a consequence of 
the events that occur in all these different 
tissues. Mechanistic studies and a search for 
appropriate anti-inflammatory agents – of 
which none have shown a modicum of suc-
cess – should not escape our attention!
In the treatment of diabetes, we have 
come a long way from the once dearth of 
agents that at one time included only insu-
lin, sulfonylureas and the biguanides. Today, 
we have a plethora of agents addressing the 
“ominous Octet” of dysfunction referred to 
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creas, adipose tissue, and musculoskeletal 
system and the recent additions of gastro-
intestinal, renal, and brain contributions to 
dysmetabolism. Thus, we need better study 
designs, carried out over long time periods 
in appropriate species – but we cannot 
afford to overlook the statistics. Less than 
one third of patients with diabetes are at 
their management targets of their glycemic 
control, a number which plummets further 
to <7% if one includes the goals for hyper-
tension and dyslipidemia that accompany 
type 2 diabetes. So why is this? Challenges in 
achieving goals are myriad (Donnan et al., 
2002; McDonald et al., 2002; Van Gaal and 
De Leeuw, 2003; Brown et al., 2004; Blonde, 
2005; Osterberg and Blaschke, 2005; Shah 
et al., 2005; Bergenstal, 2006; Vinik, 2007; 
Rakel, 2009):
•	 Clinical	inertia	of	physicians,	titration	
is a tardy task
•	 Suboptimal	use	of	available	therapies
•	 Failure	to	combine	drugs	targeting	all	
core defects of type 2 diabetes
•	 Potential	for	increased	side	effects	with	
use of multiple agents
•	 Fear	of	hypoglycemia	and	weight	gain




º  Complexity of therapy
•	 Patient	provider	relationship
The fear of hypoglycemia and weight gain 
should lead to better and newer agents 
including different forms of insulin, the 
incretin mimetics and the DPP1V inhibi-
tors which, for the most part, only stimu-
late insulin production depending upon 
the prevailing glucose level and thus per se 
do not cause hypoglycemia (Nathan et al., 
2009). The findings that hypoglycemia may 
be a marker for a much greater defect in 
metabolic counter-regulation should be an 
incentive to further understand the nature 
of the meaning of hypoglycemia and its 
consequences, as well as attempts to rectify 
them (Zoungas et al., 2010).
With the advent of modern technolo-
gies, we ought to be able to circumvent 
this apathy and lethargy of aggressive early 
treatment. Both the DCCT and the UKPDS 
(Holman et al., 2008) taught us that early 
investment is rewarded with good meta-
bolic memory, conferring a reduction in 
the complications despite later loss of gly-
cemic control. Understanding this mecha-
nism will inevitably change the way we deal 
with management issues. The alternate is 
certainly not attractive. Three major stud-
ies – ADVANCE, ACCORD, and VADT – 
taught us that intensification of glycemic 
control in people at great risk for macro-
vascular complications does not achieve a 
reduction in major adverse cardiovascular 
events (MACE; Boussageon et al., 2011; 
Bennett et al., 2012). Indeed, the increase in 
sudden death of 22% in the ACCORD study 
certainly got the attention of clinicians. The 
factors increasing this bad legacy created a 
need for circumspection in the manage-
ment of people with longstanding diabe-
tes, African Americans, women, people with 
impaired renal function, proteinuria and, 
surprisingly, people with numb feet and 
autonomic dysfunction. Development of 
risk stratification and elucidating the patho-
genesis of bad legacy will be a great change 
for basic and clinical researchers and allow 
widening of the therapeutic window and 
remove the fear of being aggressive because 
it simply is too late. A take-home message 
from the ACCORD study is the role of loss 
of autonomic balance as a factor conducive 
to risk of cardiovascular events. Autonomic 
neuropathy has long been the Cinderella of 
the complications of diabetes despite the 
fact that it has repeatedly been shown to 
increase the risk of sudden death by a HR 
of 3.48 if there is more than one abnormal-
ity. As pointed out by (Vinik et al., 2011), 
the combination of peripheral neuropathy 
and autonomic dysfunction confers a HR 
for events of 4.33, perhaps the greatest risk 
we have witnessed in recent years. This is 
what energized me to submit the lead arti-
cle on the role of neuro-inflammation and 
the brain as the conductor of the endocrine 
orchestra and the possible role of a cholin-
ergic anti-inflammatory reflex, which may 
stem the tide of the neuroendocrine cascade 
with inflammation and oxidative/nitrosa-
tive stress. I would like to see my belief in 
this pathway finally vindicated by the smart 
emerging generation of scientists who have 
at their disposal the tools to unravel these 
new and intriguing complexities.
The relationship of diabetes and its treat-
ment to cancer, C cell hyperplasia, bladder 
cancer, and pancreatic and breast cancer 
is another area that needs major focus 
(Taubes, 2012). The ability of biguanides 
to combat both diabetes and cancer suggests 
that these intriguing metabolic partners 
ought to be explored further and we will 
see the emergence of a dual class of agents 
that can mitigate both conditions.
Another topic of particular interest is 
the application of new technologies for the 
delivery of insulin and other possible pep-
tides and for continuous monitoring and 
closing the loop of the artificial pancreas. 
Islet regeneration and replication, as well 
as novel techniques for isolating and expan-
sion of islets, will prove welcome research, 
as well as studies on oxidative/nitrosative 
stress and inflammation and the identifi-
cation of novel therapies to combat these. 
From a clinical perspective, this includes 
the use of modern technology for ways and 
means of information transfer and studies, 
which enhance outreach and promote self 
management (Basevi et al., 2011). The field 
needs a means of quantification of qual-
ity of life and its enhancement (Vinik and 
Zhang, 2007), including the comorbidities 
of diabetes such as anxiety, depression, and 
sleep disturbance.
The ultimate goal of Frontiers in Diabetes 
is to provide a vehicle for accelerating com-
munication between scientists and clinicians 
globally and to provide a platform capable 
of short-circuiting the onerous aspects of 
traditional publication systems. This will 
serve to enhance the quality of research in 
the basic science and clinical care of diabe-
tes, and to encourage the merging of these 
disciplines into translational research, creat-
ing an extended Frontiers family of clinical 
scientists globally sharing our mission to 
cure diabetes and prevent its complications.
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